Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Genuine Biotech Files for Hong Kong IPO to Support Novel Drug Portfolio

publication date: Aug 5, 2022

China’s Genuine Biotech filed to IPO on the Hong Kong Exchange. Genuine, headquartered in Pingdingshan, Henan Province, develops novel drugs for viral, oncological and cerebrovascular diseases. Its lead drug, azvudine, a nucleoside analog that inhibits HIV-1 RNA-dependent RNA polymerase (RdRp), is conditionally approved in China to treat HIV and COVID-19. One year ago, Genuine raised $100 million in a B round. The company can produce 6.8 billion azvudine tablets per year at half the cost of Pfizer’s Paxlovid. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Beijing and Digital
November 8-11, 2022
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
July 27-31, 2022